Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 12/20 | 0.42 |
| ▸ | CTSK | P43235 | 10/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1304101 | 0.88 | TDP1 (0.53) | TDP1CTSSCTSKMAOAMAOB | |
| SCHEMBL7337844 | 0.86 | TDP1 (0.45) | TDP1CTSSCTSKMAPTMAOA | |
| SCHEMBL27939620 | 0.85 | CTSS (0.53) | TDP1CTSSCTSKCTSLCTSB | |
| SCHEMBL14723706 | 0.80 | TDP1 (0.66) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL18239620 | 0.80 | TDP1 (0.56) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL25327812 | 0.78 | MEN1 (0.47) | TDP1CTSSCTSKMAOAMAOB | |
| SCHEMBL5873372 | 0.78 | TDP1 (0.46) | TDP1MAPTMAOAMAOBMEN1 | |
| SCHEMBL1519817 | 0.78 | MEN1 (0.60) | TDP1CTSSCTSKMAOAMAOB | |
| SCHEMBL4589365 | 0.78 | MAOA (0.47) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL10243062 | 0.78 | TDP1 (0.46) | TDP1MAOAMAOBMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | MME, REN, ECE1 | TDP1 2971/4885CTSS 357/4885CTSK 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.